With 5.1 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.15 million shares. During the session, the Medical Instruments & Supplies company that operates in wider Healthcare sector, reached to the highest price of $3.74 whereas the lowest price it dropped to was $3.451. The 52-week range on KRMD shows that it touched its highest point at $5.05 and its lowest point at $1.86 during that stretch. It currently has a 1-year price target of $5.50. Beta for the stock currently stands at 0.50.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of KRMD was up-trending over the past week, with a rise of 7.40%, but this was up by 23.89% over a month. Three-month performance surged to 39.08% while six-month performance fell -8.10%. The stock lost -5.71% in the past year, while it has gained 21.40% so far this year. A look at the trailing 12-month EPS for KRMD yields -0.12 with Next year EPS estimates of -0.01. For the next quarter, that number is -0.02. This implies an EPS growth rate of 50.00% for this year and 92.31% for next year.
Float and Shares Shorts:
At present, 46.14 million KRMD shares are outstanding with a float of 43.90 million shares on hand for trading. On 2025-06-13, short shares totaled 0.39 million, which was 84.0 higher than short shares on 1747267200. In addition to Ms. Linda M. Tharby as the firm’s President, CEO & Director, Mr. Thomas Adams serves as its CFO, Secretary & Treasurer.
Institutional Ownership:
Through their ownership of 0.51824003 of KRMD’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2025-03-31, KRMD reported revenue of $9635075.0 and operating income of -$1245005.0. The EBITDA in the recently reported quarter was -$1033236.0 and diluted EPS was -$0.03.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for KRMD since 3 analysts follow the stock currently. There are 3 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With KRMD analysts setting a high price target of 7.0 and a low target of 3.5, the average target price over the next 12 months is 5.5. Based on these targets, KRMD could surge 92.84% to reach the target high and fall by -3.58% to reach the target low. Reaching the average price target will result in a growth of 51.52% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.10285 being high and -$0.10866 being low. For KRMD, this leads to a yearly average estimate of -$0.106.
